Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients

Introduction Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS). Methods We retrospectively analyzed the available bone mar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2019-09, Vol.103 (3), p.208-214
Hauptverfasser:	Santaliestra, Marta, Garrido, Ana, Carricondo, Maite, Bussaglia, Elena, Pratcorona, Marta, Blanco, Maria L., Gich, Ignasi, Hoyos, Montserrat, Esquirol, Albert, García‐Cadenas, Irene, Brunet, Salut, Martino, Rodrigo, Sierra, Jorge, Nomdedéu, Josep F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Aged Aged, 80 and over Antimetabolites, Antineoplastic - pharmacology Antimetabolites, Antineoplastic - therapeutic use Azacitidine - pharmacology Azacitidine - therapeutic use Azacytidine Bone marrow Bone Marrow Cells - metabolism Combined Modality Therapy Cytogenetics demethylating agents Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Male Middle Aged molecular methods MRD mRNA Multivariate analysis Myelodysplastic syndrome Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Myeloid leukemia myeloid neoplasms Myeloproliferative Disorders - drug therapy Myeloproliferative Disorders - genetics Myeloproliferative Disorders - metabolism Myeloproliferative Disorders - pathology Risk groups Statistical analysis Stem cell transplantation Survival analysis Transplantation, Homologous Treatment Outcome Tumors WT1 WT1 Proteins - genetics WT1 Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Increased levels of Wilms’ tumor (WT1) mRNA have been used to establish risk categories in patients with acute myeloid leukemia (AML). Raised values of WT1 have been associated with progression in myelodysplastic syndrome (MDS). Methods We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5‐azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below
ISSN:	0902-4441 1600-0609
DOI:	10.1111/ejh.13275